Given that elevated levels of some VEGF ligands and receptors have been associated with shorter survival [99,100,101], the candidate biomarkers in serum (soluble (s) VEGFR1, 3; VEGF-C, -D) and tumor biopsy (VEGFR2] were explored for their prognostic and potential predictive value for ramucirumab efficacy [31]. The gene discussed is FLT1; the disease is neoplasm.